CTLS specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein

Journal of Immunotherapy

Volumn 21, Issue 4, 1998, Pages 257-268

  Chen, Wei ^a,b   Qin, Huilian ^a   Reese, Valerie A ^a   Cheever, Martin A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

bcr abl protein; Cytotoxic T lymphocytes; Joining region segment

Indexed keywords

BCR ABL PROTEIN; CD8 ANTIGEN; CHIMERIC PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SYNTHETIC PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; CHROMOSOME TRANSLOCATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOGLOBULIN STRUCTURE; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION;

EID: 0031846466     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199807000-00003     Document Type: Conference Paper

References (21)

1. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994;372:143-9.
2. Deisseroth A, Arlinghaus RB. Chronic myelogenous leukemia: molecular approaches to research and therapy. New York: Dekker, 1991.
3. Kurzrock R, Kloetzer WS, Talpaz M, et al. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood 1987;70:233-6.
4. Canaani E, Marcelle C, Fainstein E. Bcr-abl RNA in chronic myelogenous leukemia and acute lymphocytic leukemia. In: Deisseroth A, Arlinghaus RB, eds. Chronic myelogenous leukemia: molecular approaches to research and therapy. New York: Dekker, 1991:217-40.
5. bcr-abl protein. Proc Natl Acad Sci USA 1992; 89:1468-72.
6. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995;85:2680-4.
7. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;87: 3587-92.
8. Ten-Bosch GJ, Toornvliet AC. Friede T, et al. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 1995;9:1344-8.
9. Pawelec G, Max H, Halder T, et al. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 1996;88:2118-24.
10. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996; 93:4102-7.
11. Glynn JP, McCoy JL, Fefer A. Cross-resistance to the transplantation of syngeneic Friend, Moloney, and Rauscher virus-induced tumors. Cancer Res 1968;28:434-9.
12. Konopka J, Witte O. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984;37:1035-42.
13. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 1987;84:6558-62.
14. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol 1989;9: 1866-74.
15. Rötzschke O, Falk K, Deres K, et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990;348:252-4.
16. Falk K, Rötzschke O, Stevanovic S, et al. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-6.
17. Rötzschke O, Falk K. Naturally-occurring peptide antigens derived from the MHC class I-restricted processing pathway. Immunol Today 1991;12:447-55.
18. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177: 265-72.
19. O'Neil BH, Kawakami Y, Restifo NP, et al. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Iminunol 1993; 151:1410-18.
20. Cheever MA, Disis ML, Bernhard H, et al. Immunity to oncogenic proteins. Immunol Rev 1995;157:177-94.
21. Disis M, Cheever M. Oncogenic proteins as tumor antigens. Curr Opin Immunol 1996;5:637-42.